Antitumor effect of sFlt-1 gene therapy system mediated by Bifidobacterium Infantis on Lewis lung cancer in mice

Cancer Gene Therapy

Volumn 18, Issue 12, 2011, Pages 884-896

  Zhu, H ^a   Li, Z ^a   Mao, S ^b,c   Ma, B ^a   Zhou, S ^b   Deng, L ^b   Liu, T ^a   Cui, D ^a   Zhao, Y ^a   He, J ^a   Yi, C ^a   Huang, Y ^b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c Center Hospital   (China)

Author keywords

antiangiogenesis; Bifidobacterium Infantis; soluble fms like tyrosine kinase receptor; vascular endothelial growth factor

Indexed keywords

ANTINEOPLASTIC AGENT; SOLUBLE FMS LIKE TYROSINE KINASE RECEPTOR 1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APPETITE; ARTICLE; BEHAVIOR CHANGE; BIFIDOBACTERIUM LONGUM INFANTIS; CANCER INHIBITION; CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN; CONTROLLED STUDY; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; MENTAL HEALTH; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; SURVIVAL; UMBILICAL VEIN ENDOTHELIAL CELL; WEIGHT;

ANIMALS; BIFIDOBACTERIUM; CARCINOMA, LEWIS LUNG; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICE, INBRED C57BL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

BIFIDOBACTERIUM LONGUM BV. INFANTIS; MUS;

EID: 81155123125     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2011.57     Document Type: Article

References (44)

1. Sonmezer M, Gungor M, Ensari A, Ortac F. Prognostic significance of tumor angiogenesis in epithelial ovarian cancer: in association with transforming growth factor [beta] and vascular endothelial growth factor. Int J Gynecol Cancer 2004; 14: 82-88. (Pubitemid 38280627)
2. Li W, Xu RJ, Zhang HH, Jiang LH. Overexpression of cyclooxygenase-2 correlates with tumor angiogenesis in endometrial carcinoma. Int J Gynecol Cancer 2006; 16: 1673-1678. (Pubitemid 44060397)
3. Cantu De Leon D, Lopez-Graniel C, Mendivil MF, Vilchis GC, Gomez C, Salazar JDLG. Significance of microvascular density (MVD) in cervical cancer recurrence. Int J Gynecol Cancer 2003; 13: 856-862. (Pubitemid 38235232)
4. Chen WT, Huang CJ, Wu MT, Yang SF, Su YC, Chai CY. Hypoxia-inducible factor-1[alpha] is associated with risk of aggressive behavior and tumor angiogenesis in gastrointestinal stromal tumor. Jpn J Clin Oncol 2005; 35: 207-213.
5. Joo YEMD, Rew JSMD, Seo YHMD, Choi SKMD, Kim YJMD, Park CSMD et al. Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer. J Clin Gastroenterol 2003; 37: 28-33.
6. Jordan K, Wolf HH, Voigt W, Kegel T, Mueller LP, Behlendorf T et al. Bevacizumab in combination with sequential high-dose chemotherapy in solid cancer, a feasibility study. Bone Marrow Transplant 2010; 45: 1704-1709.
7. Soltau J, Drevs J. Mode of action and clinical impact of VEGF signaling inhibitors. Expert Rev Anticancer Ther 2009; 9: 649-662.
8. Marom EMMD, Martinez CHMD, Truong MTMD, Lei XP, Sabloff BSMD, Munden RFMD et al. Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer. J Thorac Oncol 2008; 3: 351-357.
9. Ji L, Mao S, Liu H, Xu S, Yang Y, Yi C et al. Construction and expression of soluble vascular endothelial growth factor receptor-1 eukaryotic expression vector and its effect on proliferation of vascular endothelial cells. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 2010; 27: 369-372.
10. Harris AL. Antiangiogenesis for cancer therapy. Lancet 1997; 349: 13sII-15sII.
11. Kommareddy S, Amiji M. Antiangiogenic gene therapy with systemically administered sFlt-1 plasmid DNA in engineered gelatin-based nanovectors. Cancer Gene Ther 2007; 14: 488-498. (Pubitemid 46588197)
12. FDA approves first antiangiogenesis therapy for treating cancer. Expert Rev Anticancer Ther 2004; 4: 167.
13. Camp-Sorrell DMSNFNPA. Antiangiogenesis: the fifth cancer treatment modality? Oncol Nurs Forum 2003; 30: 934-944.
14. Li C, Bowles DE, van Dyke T, Samulski RJ. Adenoassociated virus vectors: potential applications for cancer gene therapy. Cancer Gene Ther 2005; 12: 913-925. (Pubitemid 41622258)
15. Browne M, Stellmach V, Cornwell M, Chung C, Doll JA, Lee EJ et al. Gene transfer of pigment epithelium-derived factor suppresses tumor growth and angiogenesis in a hepatoblastoma xenograft model. Pediatr Res 2006; 60: 282-287. (Pubitemid 44267739)
16. Ye C, Feng C, Wang S, Wang KZQ, Huang N, Liu X et al. sFlt-1 gene therapy of follicular thyroid carcinoma. Endocrinology 2004; 145: 817-822. (Pubitemid 38183825)
17. Liu J, Li J, Su C, Huang B, Luo S. Soluble Fms-like tyrosine kinase-1 expression inhibits the growth of multiple myeloma in nude mice. Acta Biochim Biophys Sin 2007; 39: 499-506. (Pubitemid 47117599)
18. Yoshimura I, Mizuguchi Y, Miyajima A, Asano T, Tadakuma T, Hayakawa M. Suppression of lung metastasis of renal cell carcinoma by the intramuscular gene transfer of a soluble form of vascular endothelial growth factor receptor I. J Urol 2004; 171: 2467-2470. (Pubitemid 38625516)
19. McCarthy J, O'Mahony L, O'Callaghan L, Sheil B, Vaughan EE, Fitzsimons N et al. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 2003; 52: 975-980. (Pubitemid 36765289)
20. Yi C, Huang Y, Guo ZY, Wang SR. Antitumor effect of cytosine deaminase/5-fluorocytosine suicide gene therapy system mediated by Bifidobacterium infantis on melanoma 1. Acta Pharmacol Sin 2005; 26: 629-634. (Pubitemid 40684466)
21. Hu B, Kou L, Li C, Zhu LP, Fan YR, Wu ZW et al. Bifidobacterium longum as a delivery system of TRAIL and endostatin cooperates with chemotherapeutic drugs to inhibit hypoxic tumor growth. Cancer Gene Ther 2009; 16: 655-663.
22. Li X, Fu GF, Fan YR, Liu WH, Liu XJ, Wang JJ et al. Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther 2003; 10: 105-111. (Pubitemid 36228257)
23. Liu TG, Huang Y, Cui DD, Huang XB, Mao SH, Ji LL et al. Inhibitory effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis and growth of lung cancer in mice. BMC Cancer 2009; 9: 250.
24. Pellicer A, Cabanas F, Perez-Higueras A, Garcia-Alix A, Quero J. Neural migration disorders studied by cerebral ultrasound and colour Doppler flow imaging. Arch Dis Childhood Fetal Neonat Edn 1995; 73: 55F-61F.
25. Li X, Fu GF, Fan YR, Liu WH, Liu XJ, Wang JJ et al. Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther 2003; 10: 105-111. (Pubitemid 36228257)
26. Chen G, Zhou J, Gao Q, Huang X, Li K, Zhuang L et al. Oncolytic adenovirus-mediated transfer of the antisense chk2 selectively inhibits tumor growth in vitro and in vivo. Cancer Gene Ther 2006; 13: 930-939. (Pubitemid 44373793)
27. Yoruk OMD, Dane SMD, Ucuncu HMD, Aktan BMD, Can IP. Stereological evaluation of laryngeal cancers using computed tomography via the Cavalieri method: correlation between tumor volume and number of neck lymph node metastases. J Craniofac Surg 2009; 20: 1504-1507.
28. Akbas HMD, Sahin BPD, Eroglu LMD, Odaci EMDPD, Bilgic SPD, Kaplan SPD et al. Estimation of breast prosthesis volume by the Cavalieri principle using magnetic resonance images. Aesthet Plast Surg 2004; 28: 275-280.
29. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.
30. Oreilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285. (Pubitemid 28015876)
31. Mahendra G, Kumar S, Isayeva T, Mahasreshti PJ, Curiel DT, Stockardt CR et al. Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor. Cancer Gene Ther 2005; 12: 26-34. (Pubitemid 39665240)
32. Machein MR, Plate KH. VEGF in brain tumors. J Neuro-Oncol 2000; 50: 109-120. (Pubitemid 32166295)
33. Sokoloff MH, Bradley M, Zhau HE, Simons JW, Chung LWK. VEGF inhibits human prostate cancer (HPC) growth and potentiates anti-angiogenesis therapy. J Urol 1999; 161: 53.
34. Ramachandra S, D'Souza SS, Gururaj AE, Shaila MS, Salimath BP. Paracrine action of sFLT-1 secreted by stablytransfected Ehrlich ascites tumor cells and therapy using sFLT-1 inhibits ascites tumor growth in vivo. J Gene Med 2009; 11: 422-434.
35. Zhao QMD, Egashira KMD, Inoue SMD, Usui MMD, Kitamoto SMD, Ni WMD et al. Vascular endothelial growth factor is necessary in the development of arteriosclerosis by recruiting/activating monocytes in a rat model of long-term inhibition of nitric oxide synthesis. Circulation 2002; 105: 1110-1115.
36. Zhao Q, Egashira K, Hiasa K-I, Ishibashi M, Inoue S, Ohtani K et al. Essential role of vascular endothelial growth factor and Flt-1 signals in neointimal formation after periadventitial injury. Arterioscler Thromb Vasc Biol 2004; 24: 2284-2289. (Pubitemid 39658030)
37. Medina MA, Muñ oz-Chá puli R, Quesada AR. Challenges of antiangiogenic cancer therapy: trials and errors, and renewed hope. J Cell Mol Med 2007; 11: 374-382. (Pubitemid 47153451)
38. Lu FMD, Longo MMDP, Tamayo E, Maner WBS, Al-Hendy AMDP, Anderson GDMD et al. The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. Am J Obstet Gynecol 2007; 196: 396e1-396e7.
39. Mahasreshti PJ, Kataram M, Wang MH, Stockard CR, Grizzle WE, Carey D et al. Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin Cancer Res 2003; 9: 2701-2710. (Pubitemid 36842116)
40. Liu SC, Minton NP, Giaccia AJ, Brown JM. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Therapy 2002; 9: 291-296. (Pubitemid 34256904)
41. Fukuhara T, Taketomi A, Motomura T, Okano S, Ninomiya A, Abe T et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139: 1577-1585.
42. Yazawa K, Fujimori M, Nakamura T, Sasaki T, Amano J, Kano Y et al. Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. Breast Cancer Res Treat 2001; 66: 165-170. (Pubitemid 32521423)
43. Yazawa K, Fujimori M, Amano J, Kano Y, Taniguchi S. Bifidobacterium longum as a delivery system for cancer gene therapy: Selective localization and growth in hypoxic tumors. Cancer Gene Ther 2000; 7: 269-274. (Pubitemid 30194562)
44. Wang R, Zhang XW, Wang GQ, Chen XC, Tian L, Yang HS et al. Systemic inhibition of tumor growth by soluble Flk-gene therapy combined with cisplatin. Cancer Gene Ther 2006; 13: 940-947. (Pubitemid 44373794)